Suppr超能文献

新冠病毒疾病住院期间纤维蛋白单体评估是院内死亡率的预测指标。

Fibrin monomers evaluation during hospitalization for COVID-19 is a predictive marker of in-hospital mortality.

作者信息

Smadja David M, Gendron Nicolas, Philippe Aurélien, Diehl Jean-Luc, Ochat Nadège, Bory Olivier, Beauvais Agathe, Mareau Alexis, Jannot Anne-Sophie, Chocron Richard

机构信息

Innovative Therapies in Hemostasis, INSERM, University Paris Cité, Paris, France.

Hematology Department, AP-HP.CUP, Georges Pompidou European Hospital, Paris, France.

出版信息

Front Cardiovasc Med. 2023 Mar 30;10:1001530. doi: 10.3389/fcvm.2023.1001530. eCollection 2023.

Abstract

BACKGROUND

Coagulopathy is one of the main triggers of severity and worsening of Coronavirus disease 2019 (COVID-19) particularly in critically ill patients. D-dimer has been widely used to detect COVID-19 coagulation disorders and has been correlated with outcomes such as disease severity and in-hospital mortality. Involvement of other fibrin degradation products, particularly fibrin monomers (FM), remains an ongoing question.

METHODS

We performed a monocentric study of adult patients with COVID-19, who were admitted either in the medical ward (MW) or in the intensive care unit (ICU) and who had FM measurements performed on them during the first wave of COVID-19 outbreak. We analyzed the positivity of FM levels (FM > 7 µg/mL) to assess the ability of FM monitoring during the first days of hospitalization to predict COVID-19 outcomes.

RESULTS

In our cohort, 935 FM measurements were performed in 246 patients during their first 9 days of hospitalization. During patient follow-up, the FM levels were higher in patients admitted directly to the ICU than in those admitted to the MW. Moreover, we observed significantly increased levels of FM in patients when the data were stratified for in-hospital mortality. At hospital admission, only 27 (11%) patients displayed a positive value for FM; this subgroup did not differ from other patients in terms of severity (indicated by ICU referral at admission) or in-hospital mortality. When analyzing FM positivity in the first 9 days of hospitalization, we found that 37% of patients had positive FM at least once during hospitalization and these patients had increased in-hospital mortality ( = 0.001). Thus, we used non-adjusted Kaplan-Meier curves for in-hospital mortality according to FM positivity during hospitalization and we observed a statistically significant difference for in-hospital mortality (hazard ratio = 1.48, 95% CI: 1.25-1.76,  < 0.001). However, we compared the AUC of FM positivity associated with a ratio of D-dimer >70% and found that this combined receiver operating characteristic (ROC) curve was superior to the FM positivity ROC curve alone.

CONCLUSION

Monitoring of FM positivity in hospitalized patients with COVID-19 could be a reliable and helpful tool to predict the worsening condition and mortality of COVID-19.

摘要

背景

凝血功能障碍是2019冠状病毒病(COVID-19)病情严重程度和恶化的主要触发因素之一,尤其是在重症患者中。D-二聚体已被广泛用于检测COVID-19凝血障碍,并与疾病严重程度和住院死亡率等结果相关。其他纤维蛋白降解产物,特别是纤维蛋白单体(FM)的参与情况仍是一个悬而未决的问题。

方法

我们对COVID-19成年患者进行了一项单中心研究,这些患者被收治于普通病房(MW)或重症监护病房(ICU),并在COVID-19疫情第一波期间对其进行了FM检测。我们分析了FM水平的阳性情况(FM>7μg/mL),以评估住院首日FM监测对预测COVID-19结果的能力。

结果

在我们的队列中,246例患者在住院的前9天内进行了935次FM检测。在患者随访期间,直接入住ICU的患者FM水平高于入住普通病房的患者。此外,当根据住院死亡率对数据进行分层时,我们观察到患者的FM水平显著升高。入院时,只有27例(11%)患者FM呈阳性;该亚组在严重程度(以入院时转入ICU表示)或住院死亡率方面与其他患者无差异。在分析住院前9天的FM阳性情况时,我们发现37%的患者在住院期间至少有一次FM呈阳性,这些患者的住院死亡率有所增加(P = 0.001)。因此,我们根据住院期间FM阳性情况使用未调整的Kaplan-Meier曲线分析住院死亡率,观察到住院死亡率存在统计学显著差异(风险比 = 1.48,95%CI:1.25 - 1.76,P<0.001)。然而,我们比较了FM阳性与D-二聚体>70%比值相关的曲线下面积(AUC),发现这种联合受试者工作特征(ROC)曲线优于单独的FM阳性ROC曲线。

结论

对COVID-19住院患者的FM阳性情况进行监测可能是预测COVID-19病情恶化和死亡率的可靠且有用的工具。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验